Pacira Pharmaceuticals (PCRX) Stock Statistics & Valuation Metrics

Pacira Pharmaceuticals has a market cap or net worth of $1.20B. The enterprise value is ―.

Pacira Pharmaceuticals has 46,304,670 shares outstanding. The number of shares has decreased by -2.65% in one year.

Pacira Pharmaceuticals’s return on equity (ROE) is -0.13 and return on invested capital (ROIC) is -9.24%.

The current PE Ratio of Pacira Pharmaceuticals is -8.75. Pacira Pharmaceuticals’s PEG ratio is 1.20.

In the last 12 months, Pacira Pharmaceuticals had revenue of 700.97M and earned -99.56M in profits. Earnings per share was -2.15.

In the last 12 months, operating cash flow was 189.39M and capital expenditures -10.64M, giving a free cash flow of 178.75M billion.

Pacira Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Pacira Pharmaceuticals upcoming earnings date is Aug 5, 2025, TBA Not Confirmed.

Pacira Pharmaceuticals as a current ratio of 2.40, with Debt / Equity ratio of 82.08%

In the past 12 months, Pacira Pharmaceuticals has paid 36.45M in taxes.

Pacira Pharmaceuticals EV to EBITDA ratio is 37.24, with an EV/FCF ratio of 6.07.

Pacira Pharmaceuticals has $484.62M in cash and marketable securities with $638.85M in debt, giving a net cash position of $154.24M billion.

Gross margin is 71.60%, with operating margin of -10.47%, and net profit margin of -14.20%.

The average price target for Pacira Pharmaceuticals is $35.50, which is 11.43% higher than the current price. The consensus rating is Hold